Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-138487 · Präparat HOS-098200
This recommendation is different from ritonavir-boosted darunavir. Consult the Summary of Product Characteristics for darunavir for further details. ANTI-NEOPLASTICS Dasatinib Based on theoretical considerations Concentrations of these medicinal Nilotinib DRV/COBI is expected to increase products may be increased when Vinblastine these anti-neoplastic plasma co-administered with Symtuza Vincristine concentrations. resulting in the potential for (CYP3A inhibition) increased adverse events usually associated with these medicinal products. Caution should be exercised when combining one of these anti-neoplastic agents with Symtuza.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 00a315d74a37a3357d5f3e656bba8b6b8346a8691f33f70d30e2febf7a8478af · Zeichen 22016–23449 im Abschnitt